Resolute Onyx™ Coronary Drug-Eluting Stent

Resolute Onyx™ drug-eluting stent (DES) is a stent and balloon catheter delivery system designed to be placed inside a diseased coronary artery to keep the artery open so that blood can access the heart.

Contact Us

Overview

See what makes Resolute Onyx DES different:

STENT FLEXIBILITY AND CONFORMABILITY

The Only DES Designed from a Single Wire† 

Resolute Onyx DES is composed of a single wire strand formed into a continuous sinusoidal waveform, providing a fluid range of motion with greater flexibility and conformability when compared to laser-cut stents.

Image of a continuous sinusoid single wire

Single-wire design

Image of laser cut design on white background

vs. Laser-cut design

Single wire design Benefits

Single wire design increases deliverability, flexibility, conformability, wall-apposition, and may reduce arterial injury and thrombus formation.‡1

Image of Resolute Onyx sinusoid-formed wire

Sinusoid formed wire

Image of Resolute Onyx helical wrap

Helical wrap

Image of Resolute Onyx laser-fused product

Laser-fused

ENHANCED VISIBILITY

THE ONLY DES WITH A PLATINUM IRIDIUM CORE   

The platinum iridium core within Resolute Onyx DES increases radiopacity for accurate stent placement.

Average Visibility Comparison

Higher is Better

Graph of  independent study showing average visibility comparison

 

 

Image call out of cobalt alloy shell and platinum iridum core

SIDE BRANCH ACCESS

THE ONLY DES WITH TRULY ROUNDED STRUTS

Resolute Onyx DES is designed with rounded struts that may create a smooth passage for side branch access.

strut shape

Round Strut Cross-Section
 
 
  1. Resolute Onyx™ DES
Illustration showing round strut shape

Square Strut Cross-Section

  1. Synergy™* DES
  2. Xience Sierra™* DES
Illustration showing square strut shape

cell shape

Regular Cell Shape
Resolute Onyx DES

Image showing regular cell shape

Irregular Cell Shape
Xience Sierra™* DES

Image showing irregular cell shape

BROADEST SIZE MATRIX

The only DES offering 2.0-5.0 mm diameters 

The Resolute Onyx DES broad size matrix optimizes stent deployment and expansion.

Table showing drug-eluting stent size ranges

Designed Specifically for Large Vessels

Image of maximum expansion left main stent

5.75 mm maximum expansion for 4.50 and 5.00 mm sizes§

Designed Specifically for Small Vessels

Graphic showing small maximum vessel expansions 2.0mm - 3.25 mm

3.25 mm maximum expansion for 2.0 mm sizes§

EXCLUSIVE POLYMER AND ZOTAROLIMUS DRUG COMBINATION

PROVEN COMPONENTS FOR OPTIMAL HEALING

Watch a short video to learn more about the BioLinx polymer.

The Resolute Onyx DES zotarolimus drug effectively inhibits neointimal growth while the exclusive, highly biocompatible BioLinx™ polymer contributes to minimal inflammation, low thrombotic risk1, as well as rapid, complete, and functional endothelial healing.||

Fast Healing Confirmed

The 1-month OCT Study investigated early vessel healing in patients with complex coronary artery disease treated with Resolute Onyx DES.

92.3% Stent Coverage at 1 Month2

Graph comparing covered struts vs.covered stent surface

Strut Coverage

Graphic of healing strut

DOWNLOAD RESOURCES

pdf Onyx ONE Month DAPT Program Brochure (.pdf)

Download the Onyx ONE Month DAPT Program brochure to learn more about the clinical program and view the results from the Onyx ONE Global Study and Onyx ONE Clear Study. Resolute Onyx DES is not currently indicated for high bleeding risk patients on 1-month DAPT in the United States.

350KB

Onyx ONE Month DAPT Program

Evaluating Resolute Onyx DES in ~1,700 patients with 1-month DAPT

View the Data

EDUCATION

Explore the Transradial ARC Curriculum℠, designed to help you increase your procedural confidence.

See Training Programs

Complex PCI

The Resolute Onyx DES offers flexibility, conformability, deliverability, and enhanced visibility for complex percutaneous coronary intervention (PCI).

Learn More About Complex PCI

Resolute Onyx DES is not currently indicated for high bleeding risk patients on 1-month DAPT.

*

Medtronic and Medtronic logo are trademarks of Medtronic.  Third-party trademarks ("™*") belong to their respective owners.  All other brands are trademarks of a Medtronic entity.

Including Resolute Integrity DES, part of the Medtronic DES portfolio

Bench test data on file at Medtronic. Bench test data may not be indicative of clinical performance.

§

Resolute Onyx™ stents should not be expanded to a diameter beyond the maximum labeled diameter listed on the label per the IFU. Post-dilation required for overexpansion.

||

In porcine models. Based on test data on file at Medtronic. May not be indicative of clinical performance.

1

Silber S, Kirtane AJ, Belardi JA, et al. Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. Eur Heart J. August 1, 2014;35(29):1949-1956.

2

Roleder T, Kedhi E, Berta B, et al. Short-term stent coverage of second-generation zotarolimus-eluting durable polymer stents: Onyx one-month optical coherence tomography study. Adv Interv Cardiol. 2019;15(2):143-150.